Curis (NASDAQ:CRIS) Earns Buy Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Curis (NASDAQ:CRIS) in a research note released on Friday,Benzinga reports. They currently have a $20.00 price target on the biotechnology company’s stock.

Curis Trading Down 0.8 %

Curis stock traded down $0.03 during mid-day trading on Friday, reaching $3.95. The company had a trading volume of 96,523 shares, compared to its average volume of 40,150. The business has a fifty day simple moving average of $5.01 and a 200 day simple moving average of $7.12. The company has a market cap of $23.62 million, a P/E ratio of -0.48 and a beta of 3.35. Curis has a fifty-two week low of $3.51 and a fifty-two week high of $17.49.

Institutional Trading of Curis

A number of hedge funds have recently made changes to their positions in CRIS. Vanguard Group Inc. increased its stake in shares of Curis by 4.8% in the first quarter. Vanguard Group Inc. now owns 218,573 shares of the biotechnology company’s stock valued at $2,376,000 after buying an additional 10,097 shares during the period. Focused Wealth Management Inc grew its holdings in Curis by 63.1% during the 3rd quarter. Focused Wealth Management Inc now owns 54,066 shares of the biotechnology company’s stock worth $291,000 after acquiring an additional 20,908 shares during the last quarter. CM Management LLC increased its position in Curis by 380.0% in the 1st quarter. CM Management LLC now owns 120,000 shares of the biotechnology company’s stock valued at $1,304,000 after acquiring an additional 95,000 shares during the period. Finally, Point72 Asset Management L.P. raised its position in Curis by 795.5% during the 2nd quarter. Point72 Asset Management L.P. now owns 108,356 shares of the biotechnology company’s stock worth $748,000 after purchasing an additional 96,256 shares during the last quarter. 29.97% of the stock is owned by institutional investors and hedge funds.

About Curis

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.